MEDIGEN, INC. — Department of Health and Human Services SBIR Phase II: This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve T
MEDIGEN, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,483,094
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- —
- Place of performance
- MD
- Period
- —
Description
This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve TRAMP tumor challenge of vaccinated PSA+ transgenic mice. Engineered for increased immunogenicity PSA variants will be delivered and expressed in PSA+ mice using novelvector VLP (vVLP_ vaccine platform. The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes.